Equity Profile

IDYA

IDEAYA Biosciences, Inc.

Health CareBiotechnology$2.5B

Aug10Mon

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

IDEAYA Biosciences, Inc. is a biotechnology company focused on developing targeted therapies for cancer....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and commercialize its therapies.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

IDYA Q2-2026 Earnings Preview

Context

Company Snapshot

IDEAYA Biosciences, Inc. is a biotechnology company focused on developing targeted therapies for cancer. Operating in the health care sector, the company aims to address significant unmet medical needs through innovative treatments.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

+8281.73%

Avg Stock Reaction

-2.69%

Last Quarter Recap

In Q1-2026, IDEAYA reported an EPS of -$1.11, slightly missing estimates. The stock reacted with a minor decline of 0.35% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, particularly given the company's focus on innovative cancer therapies. However, the lack of analyst estimates adds uncertainty.

Bull Case

If IDEAYA can demonstrate strong progress in clinical trials and better-than-expected EPS, it could lead to increased investor confidence and a significant stock price increase.

Bear Case

Conversely, if the company reports wider losses or delays in clinical trials, it may lead to a sharp decline in stock price, reflecting investor disappointment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the latest update on the clinical trials for IDEAYA's lead therapies?

Progress in clinical trials can significantly influence investor sentiment and the company's future revenue potential.

How does management plan to address the recent EPS misses and improve financial performance?

Investors will be looking for concrete strategies to enhance profitability and reduce losses moving forward.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for IDEAYA's therapies to gain traction in the market, especially if clinical trial results are favorable.

Supporting Evidence

The options market is pricing in a 13.3% move, indicating expectations of significant volatility that may not be reflected in current stock sentiment.

The company's recent history of EPS surprises suggests that analysts may not fully account for the potential upside.

Key Risk

If clinical trial results show significant advancements, it could challenge the current cautious consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be critical in assessing the company's ability to manage costs while advancing its clinical programs.

Bull Confirmed If

Demonstrating a narrower EPS loss than the previous quarter, ideally below -$1.00, would confirm the bull case.

Bear Confirmed If

An EPS loss greater than -$1.20 would reinforce the bear case and raise concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±13.3%

Historical Avg

±4.3%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±13.3% while IDYA has averaged ±4.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

36.9%

Calls (2K)P/C Ratio: 0.10Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If IDEAYA beats expectations and raises guidance, history suggests a potential stock increase of around 1.2% on the first day.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may see a muted reaction, reflecting cautious sentiment.

Miss

A miss on EPS could lead to a decline of approximately 5.0% based on historical patterns, indicating investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of clinical trials for lead therapies.
2Management's strategy for improving financial performance and addressing EPS misses.
3Any new partnerships or collaborations that could enhance growth prospects.
4Insights into market demand for IDEAYA's therapies and competitive positioning.
5Future guidance on revenue expectations and cost management strategies.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug7

PAABMO

Plains All American Pipeline, L.P.

PreviewView

Aug7

ESNTBMO

Company Snapshot

IDEAYA Biosciences, Inc. is a biotechnology company focused on developing targeted therapies for cancer....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and commercialize its therapies.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

IDYA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

+8281.73%

Avg Stock Reaction

-2.69%

Last Quarter Recap

In Q1-2026, IDEAYA reported an EPS of -$1.11, slightly missing estimates. The stock reacted with a minor decline of 0.35% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, particularly given the company's focus on innovative cancer therapies. However, the lack of analyst estimates adds uncertainty.

Bull Case

If IDEAYA can demonstrate strong progress in clinical trials and better-than-expected EPS, it could lead to increased investor confidence and a significant stock price increase.

Bear Case

Conversely, if the company reports wider losses or delays in clinical trials, it may lead to a sharp decline in stock price, reflecting investor disappointment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the latest update on the clinical trials for IDEAYA's lead therapies?

Progress in clinical trials can significantly influence investor sentiment and the company's future revenue potential.

How does management plan to address the recent EPS misses and improve financial performance?

Investors will be looking for concrete strategies to enhance profitability and reduce losses moving forward.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for IDEAYA's therapies to gain traction in the market, especially if clinical trial results are favorable.

Supporting Evidence

The options market is pricing in a 13.3% move, indicating expectations of significant volatility that may not be reflected in current stock sentiment.

The company's recent history of EPS surprises suggests that analysts may not fully account for the potential upside.

Key Risk

If clinical trial results show significant advancements, it could challenge the current cautious consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be critical in assessing the company's ability to manage costs while advancing its clinical programs.

Bull Confirmed If

Demonstrating a narrower EPS loss than the previous quarter, ideally below -$1.00, would confirm the bull case.

Bear Confirmed If

An EPS loss greater than -$1.20 would reinforce the bear case and raise concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±13.3%

Historical Avg

±4.3%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±13.3% while IDYA has averaged ±4.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

36.9%

Calls (2K)P/C Ratio: 0.10Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If IDEAYA beats expectations and raises guidance, history suggests a potential stock increase of around 1.2% on the first day.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may see a muted reaction, reflecting cautious sentiment.

Miss

A miss on EPS could lead to a decline of approximately 5.0% based on historical patterns, indicating investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of clinical trials for lead therapies.
2Management's strategy for improving financial performance and addressing EPS misses.
3Any new partnerships or collaborations that could enhance growth prospects.
4Insights into market demand for IDEAYA's therapies and competitive positioning.
5Future guidance on revenue expectations and cost management strategies.